zh-twzhen
zh-twzhen

News

2022

Date

Title

2022-12-23

Oneness Biotech to Present at the 41st Annual J.P. Morgan Healthcare Conference

>
2022-12-21

Oneness announces the information about the investor’s conference of 2022 Q4.

>
2022-12-20

Oneness Biotech Co., Ltd. receives a Malaysian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2022-12-20

Oneness and Microbio (Shanghai) signed an agreement with Cho Pharma to jointly develop glycosylation-based nucleic acid delivery technology.

>
2022-12-06

Oneness has been invited for a poster presentation with on-site Q&A for the Phase 3 MRCT post-hoc analysis of the DFU new drug, Fespixon at IDF Congress 2022.

>
2022-12-02

The post-market hard-to-heal cases treated by the DFU new drug, Fespixon have been accepted for an oral presentation at 2022 CDS

>
2022-11-29

The trading of Oneness securities in centralized securities exchange market follows Announcement or Notice of Attention to Trading Information

>
2022-11-09

The Board of Directors of Oneness has approved a donation to Teh-Tzer Study Group for Human Medical Research Foundation.

>
2022-11-09

The Company’s 2022Q3 consolidated financial statements have been approved by the Board of Directors

>
2022-11-09

Announce the change of the corporate governance officer.

>
2022-10-27

Oneness Biotech Co., Ltd. receives Israeli, Mexican and Hong Kong patents on the producing recombinant glycoproteins with modified glycosylation.

>
2022-09-29

News-The first in the world! New drug for diabetic foot ulcer: research and development code “ON101”

>
2022-09-28

Fespixon’s clinical meaningfulness as a macrophage- regulation new drug compared with other DFU treatments has been reviewed and published in Pharmaceutics.

>
2022-09-23

Oneness announces the information about the investor’s conference of 2022 Q3.

>
2022-09-23

SNS812, a broad-spectrum siRNA co-developed by Oneness and Microbio (Shanghai) to treat SARS-CoV-2 infection, was greenlighted by FDA to proceed with a Ph1 study

>